中华骨质疏松和骨矿盐疾病杂志
中華骨質疏鬆和骨礦鹽疾病雜誌
중화골질소송화골광염질병잡지
Chinese Journal of Osteoporosis and Bone Mineral Research
2015年
3期
267-271
,共5页
甲状旁腺素%特立帕肽%促骨形成药%联合%序贯
甲狀徬腺素%特立帕肽%促骨形成藥%聯閤%序貫
갑상방선소%특립파태%촉골형성약%연합%서관
parathyroid hormone%teriparatide%anabolic agents%combination%sequential
与抗骨吸收药物不同,甲状旁腺素是促骨形成机制的骨质疏松治疗药物。近期不少研究采用促骨形成与抗骨吸收药物的联合或序贯疗法,以期望获得更好的治疗效果。考虑到国内缺少相应的临床报道,本文回顾联合与序贯治疗的研究进展,以为临床骨质疏松治疗提供参考。
與抗骨吸收藥物不同,甲狀徬腺素是促骨形成機製的骨質疏鬆治療藥物。近期不少研究採用促骨形成與抗骨吸收藥物的聯閤或序貫療法,以期望穫得更好的治療效果。攷慮到國內缺少相應的臨床報道,本文迴顧聯閤與序貫治療的研究進展,以為臨床骨質疏鬆治療提供參攷。
여항골흡수약물불동,갑상방선소시촉골형성궤제적골질소송치료약물。근기불소연구채용촉골형성여항골흡수약물적연합혹서관요법,이기망획득경호적치료효과。고필도국내결소상응적림상보도,본문회고연합여서관치료적연구진전,이위림상골질소송치료제공삼고。
Different from antiresorptive therapy , parathyroid hormone is belongs to anabolic categery , which enhances bone formation in osteoporosis treatment .Recent clinical studies try to use sequential or combination therapy with anabolic and antiresorptive to improve efficacy .Considering limited domestic reports in this area , this paper reviews the progress in combination or sequential therapy , which can be reference for osteoporosis treatment in clinical practice .